KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Shares Outstanding (Weighted Average) (2016 - 2025)

AbbVie (ABBV) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.0% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 0.0% change, with the full-year FY2025 number at $1.8 billion, changed 0.0% from a year prior.
  • Shares Outstanding (Weighted Average) was $1.8 billion for Q4 2025 at AbbVie, roughly flat from $1.8 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.8 billion in Q1 2022 to a low of $1.8 billion in Q2 2023.
  • A 5-year average of $1.8 billion and a median of $1.8 billion in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 19.45% in 2021, then fell 0.17% in 2023.
  • AbbVie's Shares Outstanding (Weighted Average) stood at $1.8 billion in 2021, then increased by 0.06% to $1.8 billion in 2022, then dropped by 0.17% to $1.8 billion in 2023, then increased by 0.06% to $1.8 billion in 2024, then changed by 0.0% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Shares Outstanding (Weighted Average) are $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025).